查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1928656

標靶化SSTR放射性核素藥物偶聯物市場（按放射性金屬類型、胜肽類似物、治療適應症、臨床階段、最終用戶和分銷管道分類），全球預測，2026-2032年

Targeted SSTR Radionuclide Drug Conjugates Market by Radiometal Type, Peptide Analog, Treatment Indication, Clinical Phase, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，標靶 SSTR 放射性核素藥物偶聯物市場價值將達到 7.9975 億美元，到 2026 年將成長至 8.5847 億美元，到 2032 年將達到 13.2025 億美元，複合年成長率為 7.42%。

關鍵市場統計數據
基準年 2025 7.9975億美元
預計年份：2026年 8.5847億美元
預測年份 2032 1,320,250,000 美元
複合年成長率 (%) 7.42%

標靶SSTR放射性核種藥物偶聯物正逐漸成為精準醫療平台，可望改變神經內分泌腫瘤的治療。

標靶生長抑制素受體放射性核素藥物偶聯物已成為核子醫學、胜肽化學和精準腫瘤學領域最先進的融合療法之一。這類藥物將生長抑制素受體結合胜肽與治療性放射性金屬結合，能夠選擇性地將放射線遞送至過度表現生長抑制素受體（尤其是SSTR2）的癌細胞。分子標靶和局部放射性核素釋放的結合，為神經內分泌腫瘤和某些內分泌惡性腫瘤的傳統全身性治療提供了強力的替代方案。

科學、臨床和系統層面的變革性變化正在重新定義SSTR靶向放射性偶聯物的競爭格局。

由於放射化學、胜肽工程、影像學和醫療保健政策等領域的進步匯聚，標靶化生長抑素受體（SSTR）放射性核素-藥物偶聯物領域正經歷變革性的變化。其中一個最顯著的趨勢是從BETA發射放射性核素向更多樣化的放射性金屬工具箱的演變。儘管鎦-177仍然是許多已通過核准和處於後期研發階段的項目的主要藥物，但人們對用於治療進行性/難治性疾病和微轉移患者的α發射體錒-225的興趣日益濃厚。釔-90在需要深層組織穿透的領域中仍然發揮作用，但其劑量限制性毒性要求對患者進行更嚴格的篩選，並採用更合理的給藥策略。

到 2025 年，美國關稅的累積影響將迫使 SSTR 放射性標記藥物開發商重組其供應鏈、成本結構和籌資策略。

美國關稅將於2025年生效，其累積影響將對目標SSTR放射性核種藥物偶聯物生態系統造成複雜的壓力和調整。這些關稅將影響放射性藥物生產的關鍵投入和設備，可能波及從放射性金屬來源、螯合劑原料到迴旋加速器和發生器組件等各個方面。雖然具體的關稅項目和稅率各不相同，但整體影響將是成本波動性增加，以及在美國市場進行供應或採購的開發商面臨供應鏈風險。

細分市場分析揭示了放射性金屬、胜肽、適應症和獲取途徑偏好對SSTR放射性標記藥物採用的影響

要全面了解標靶SSTR放射性核種藥物偶聯物的應用，需要從技術、臨床和商業性等多個層面進行綜合觀點。放射性金屬的選擇至關重要，鎦-177因其優異的半衰期、BETA射線發射特性以及與現有醫院基礎設施的兼容性，目前已成為成熟臨床實踐的核心。錒-225雖然應用尚不成熟，但由於其強大的α射線發射特性以及對微轉移和低血管化病灶的標靶治療能力，正日益受到進行性或難治性疾病患者的關注。釔-90在需要深層組織穿透的治療中仍然發揮著重要作用，但其應用需要在療效和潛在的脫靶毒性之間取得平衡，因此患者選擇和劑量測定至關重要。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢正在決定SSTR放射治療藥物的可近性、實施能力和成長路徑。

區域趨勢在靶向SSTR放射性核素藥物偶聯物的發展和應用過程中發揮了至關重要的作用，美洲、歐洲/中東/非洲和亞太地區呈現出截然不同的模式。在美洲，美國處於臨床應用和創新的中心，這得益於其強大的學術核醫學中心、有利的放射性藥物法規環境以及支持複雜供應鏈的一體化生產商。在主要癌症中心，基於鎦-177的治療方案已相對成熟，並且正在投入大量資金以擴大基於錒-225和其他α放射性核素的治療項目。雖然加拿大和一些拉丁美洲國家的應用也逐漸增加，但由於基礎設施、報銷和專家資源方面的差異，導致該地區內治療機會不均等。

企業策略、合作夥伴關係和生產模式塑造了SSTR標靶放射性核種藥物偶聯物的競爭定位。

企業策略是針對SSTR放射性核種藥物偶聯物領域發展演變的關鍵決定因素，大型製藥企業和專業放射性藥物公司都在塑造該領域的發展方向。產業領導企業正利用其資源、監管經驗和現有的腫瘤產品組合，投資其鎦-177基產品線的商業性擴張、適應症拓展和生命週期管理專案。這些措施包括上市後監測、真實世界資料收集以及與領先的癌症中心合作，以完善患者選擇標準並加強長期安全性監測。

超臨界流體放射性核種治療領域產業領導者的實用策略：產品線、韌性與准入最佳化

在靶向SSTR放射性核素藥物偶聯物領域，產業領導企業可以採取多項切實措施來鞏固其策略地位並提升對患者的益處。首要任務是深化放射化學創新與臨床開發計畫的整合。放射性金屬或胜肽類似物的選擇不應被視為孤立的技術決策，而應與明確的臨床假設和目標患者群體（尤其是在神經內分泌腫瘤和甲狀腺癌領域）保持一致。儘早與關鍵意見領袖（KOL）互動有助於完善這些假設，確保在研產品能夠滿足未被滿足的醫療需求，並融入實際的治療路徑。

為深入了解SSTR標靶放射性核種藥物偶聯物所採取的穩健、多方面的調查方法

支持本執行摘要的分析基於結構化的多層次調查方法，調查方法捕捉標靶化SSTR 放射性核素藥物偶聯物的科學、臨床、監管和商業性細微差別，整合廣泛的二手資訊和主要專家檢驗和背景分析，同時保持嚴格的品管標準和三角測量技術。

創新、證據和可及性的融合使SSTR放射性核素偶聯物處於腫瘤學的轉折點。

標靶生長抑素受體（SSTR）放射性核素藥物偶聯物正從特殊治療方法轉變為現代腫瘤治療的重要組成部分，特別是在神經內分泌腫瘤和某些甲狀腺癌的治療中。這些藥物利用生長抑制素受體結合胜肽的特異性和治療性放射性核素的細胞毒性，為合適的患者提供療效顯著、器官保留和生活品質改善的完美結合。放射性金屬化學、胜肽工程和劑量測定技術的進步為更廣泛的臨床應用奠定了基礎，而不斷成熟的研發管線則展現了BETA和α發射平台的持續創新。

然而，這種演變也帶來了挑戰，需要產業、醫療保健提供者、監管機構和支付方協調應對，尤其是在供應鏈變得越來越複雜的情況下。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依放射性金屬類型標靶化SSTR放射性核種藥物偶聯物市場

  • 錒-225
  • 鎦-177
  • 釔90

第9章 胜肽類似物標靶化SSTR放射性核素藥物偶聯物市場

  • 多塔諾克
  • 多塔塔特
  • Dotatock

第10章 依治療適應症分類的標靶化SSTR放射性核種藥物偶聯物市場

  • 神經內分泌腫瘤
  • 甲狀腺癌

第11章標靶化SSTR放射性核素藥物偶聯物市場（按臨床階段分類）

  • 商業的
  • 第一階段
  • 第二階段
  • 第三階段
  • 臨床前階段

第12章標靶化SSTR放射性核素藥物偶聯物市場（按最終用戶分類）

  • 醫院
  • 研究所
  • 專科診所

第13章標靶化SSTR放射性核種藥物偶聯物市場（按分銷管道分類）

  • 直接採購
  • 透過分銷商銷售
  • 競標

第14章 區域性標靶化SSTR放射性核素藥物偶聯物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章標靶化SSTR放射性核素藥物偶聯物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國標靶化SSTR放射性核種藥物偶聯物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

17. 美國標靶化SSTR放射性核種藥物偶聯物市場

18. 中國標靶化SSTR放射性核種藥物偶聯物市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Actinium Pharmaceuticals, Inc.
  • ACUITY Pharmaceuticals, Inc.
  • Bayer AG
  • Cardinal Health, Inc.
  • Curium Pharma GmbH
  • Eckert & Ziegler Radiopharma GmbH
  • GE Healthcare Limited
  • Ipsen SA
  • Isoray Medical, Inc.
  • ITM Isotope Technologies Munich SE
  • Jubilant Life Sciences Limited
  • Lantheus Holdings, Inc.
  • Novartis AG
  • Point Biopharma Inc.
  • PSMA Therapeutics LLC
  • RadioMedix, Inc.
  • RayzeBio, Inc.
  • Sorrento Therapeutics, Inc.
  • Telix Pharmaceuticals Limited
  • Theragnostics, Inc.
  • Viamet Pharmaceuticals, Inc.
Product Code: MRR-92740D85F095

The Targeted SSTR Radionuclide Drug Conjugates Market was valued at USD 799.75 million in 2025 and is projected to grow to USD 858.47 million in 2026, with a CAGR of 7.42%, reaching USD 1,320.25 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 799.75 million
Estimated Year [2026] USD 858.47 million
Forecast Year [2032] USD 1,320.25 million
CAGR (%) 7.42%

Targeted SSTR radionuclide drug conjugates emerge as a precision oncology cornerstone transforming neuroendocrine care

Targeted somatostatin receptor radionuclide drug conjugates are emerging as one of the most sophisticated intersections of nuclear medicine, peptide chemistry, and precision oncology. These agents combine a somatostatin receptor-binding peptide with a therapeutic radiometal to selectively deliver radiation to tumor cells that overexpress somatostatin receptors, particularly SSTR2. By pairing molecular targeting with localized radionuclide emission, they offer a powerful alternative to conventional systemic therapies for neuroendocrine and select endocrine malignancies.

The clinical momentum behind these conjugates has accelerated in recent years. Multiple compounds based on Lutetium 177 have achieved regulatory approval in major markets, while a broader wave of assets across Actinium 225 and Yttrium 90 backbones is progressing through the pipeline. At the same time, refinements in peptide analogs such as Dotatate, Dotatoc, and Dotanoc, alongside advances in radiochemistry and chelation techniques, are driving more precise receptor binding, improved dosimetry, and potentially more favorable safety profiles.

This executive summary provides a strategic overview of how targeted SSTR radionuclide drug conjugates are reshaping the therapeutic landscape. It examines the scientific and clinical foundations, outlines the most important technological shifts, explores policy-related pressures such as upcoming United States tariffs, and synthesizes segmentation, regional, and competitive insights. Moreover, it offers practical recommendations designed to help industry leaders convert emerging opportunities into durable competitive advantage.

As oncology care continues to trend toward personalization and value-based outcomes, these conjugates sit at a critical inflection point. They offer the prospect of improved survival and quality of life for patients with otherwise limited options, while simultaneously challenging healthcare systems, regulators, and manufacturers to build new capabilities in radiopharmaceutical supply chains, safety, and multidisciplinary delivery models.

Transformative scientific, clinical, and system-level shifts redefine the competitive landscape for SSTR-targeted radioconjugates

The landscape for targeted SSTR radionuclide drug conjugates is undergoing transformative shifts driven by converging advances in radiochemistry, peptide engineering, imaging, and health policy. One of the most notable trends is the evolution from beta-emitting radionuclides toward a more diversified radiometal toolbox. While Lutetium 177 remains the workhorse for many approved and late-stage programs, there is growing interest in Actinium 225 alpha emitters for patients with aggressive, refractory disease and micrometastatic burden. Yttrium 90 continues to play a role where deeper tissue penetration is advantageous, but dose-limiting toxicity considerations are prompting more rigorous patient selection and dosing strategies.

In parallel, peptide analog innovation is reshaping the therapeutic profile of these conjugates. Dotatate has become a reference scaffold in clinical practice, particularly for midgut neuroendocrine tumors, yet Dotatoc and Dotanoc are increasingly evaluated for subtype-specific binding affinities and biodistribution advantages. Researchers are exploring how nuanced differences in receptor subtype selectivity and internalization kinetics can improve tumor-to-normal tissue ratios, raising the prospect of more personalized radioligand therapy paired with advanced imaging-based dosimetry.

Another major shift is the growing emphasis on earlier-line use and broader treatment indications. Historically, these agents were reserved for later-line neuroendocrine tumors, but accumulating clinical evidence and real-world data are encouraging trials in earlier disease stages and in additional indications such as differentiated and medullary thyroid cancer. This movement is supported by improvements in patient stratification, where high-resolution SSTR-PET imaging and molecular diagnostics are enabling more precise determination of which patients are likely to derive the greatest benefit.

The clinical development landscape is also evolving rapidly. The presence of commercially available SSTR-targeted radionuclide therapies has not dampened innovation; rather, it has catalyzed a rich pipeline spanning preclinical projects through Phase I, II, and III trials. Developers are experimenting with novel chelators, combination regimens with immunotherapies and targeted small molecules, and optimized dosing schedules to balance efficacy with long-term safety, particularly with respect to renal and hematologic toxicity.

Concurrently, the delivery environment is moving toward more integrated care models. Hospitals, specialty clinics, and research institutes are reconfiguring workflows to support multidisciplinary teams involving nuclear medicine, medical oncology, endocrinology, radiology, and radiation safety experts. This integration is essential to manage complex logistics, including radionuclide handling, patient counseling, therapy scheduling, and post-treatment surveillance.

Regulatory agencies and payers are responding to these shifts by refining frameworks around radiopharmaceutical manufacturing, quality assurance, and value assessment. More explicit guidance on good manufacturing practices for short-lived radionuclides, standardized dosimetry, and harmonized outcome measures is emerging. Simultaneously, payers are scrutinizing real-world effectiveness and cost-utility, moving toward reimbursement models that reward durable responses and reduced hospitalization, thereby reinforcing the trend toward evidence-rich, value-driven deployment of SSTR-targeted radionuclide drug conjugates.

Taken together, these changes indicate a transition from niche, late-line experimentation to structured integration within standard oncology pathways. Companies and institutions that anticipate and adapt to these shifts are likely to define the next era of competitive leadership in the field.

Cumulative 2025 US tariff effects reshape supply chains, cost structures, and sourcing strategies for SSTR radioconjugate developers

The cumulative impact of United States tariffs becoming effective in 2025 introduces a complex set of pressures and realignments for the targeted SSTR radionuclide drug conjugate ecosystem. These tariffs, which touch critical inputs and equipment relevant to radiopharmaceutical production, can affect everything from radiometal sourcing and chelator raw materials to cyclotron and generator components. While the specific tariff lines and rates vary, the overarching effect is to heighten cost volatility and supply chain risk for developers supplying or sourcing within the U.S. market.

One immediate implication is pressure on the cost base for Lutetium 177, Yttrium 90, and emerging Actinium 225 supply chains. Tariff-related cost increases for reactor-produced or accelerator-produced isotopes, specialized precursors, and packaging materials can cascade through contract manufacturing organizations and centralized radiopharmacies. For companies already operating with tight margins due to short half-life logistics and stringent quality requirements, even modest tariff-driven cost changes can constrain pricing flexibility and squeeze profitability.

Beyond direct cost impacts, the tariffs are catalyzing strategic reassessments of sourcing and manufacturing networks. Organizations are exploring alternative suppliers in tariff-neutral jurisdictions, considering localizing certain production steps within the United States to reduce exposure, and renegotiating long-term supply contracts to incorporate cost-sharing and contingency clauses. This realignment is particularly relevant for SSTR-targeted conjugates that depend on reliable, time-sensitive delivery of Lutetium 177 or Actinium 225 to hospitals and specialty clinics for on-time patient dosing.

Moreover, tariffs may influence the economics of late-stage clinical trials and commercial scale-up. Increased costs for radiometal and peptide inputs, as well as for specialized imaging and manufacturing equipment, can raise the capital intensity of expanding Phase II and Phase III programs or adding new production sites. Smaller biotechnology sponsors may find it more challenging to absorb these costs, which could, in turn, accelerate partnership activity with larger pharmaceutical companies or integrated radiopharmaceutical manufacturers that can leverage economies of scale.

Tender-driven procurement, particularly within public healthcare systems and large hospital networks, will feel the effects as tariff-related price changes feed into bidding strategies and contract terms. Payers and institutional buyers may respond by emphasizing total treatment value rather than unit dose costs, but they will simultaneously expect suppliers to demonstrate supply reliability and contingency planning in the face of geopolitical and trade-policy uncertainty.

On the positive side, the 2025 tariff environment is prompting innovation in supply chain resilience and cost optimization. Developers are investing in process efficiencies, higher-yield radiolabeling techniques, and integrated logistics platforms to offset input cost increases. Some are also exploring diversified radiometal strategies, such as shifting a portion of pipelines toward isotopes with more favorable supply or regulatory dynamics, provided clinical performance remains robust.

Ultimately, while U.S. tariffs introduce friction into the targeted SSTR radionuclide drug conjugate value chain, they also act as a catalyst for more deliberate, risk-aware planning. Companies that proactively adjust sourcing strategies, strengthen supplier diversification, and embed tariff scenarios into their financial models will be better positioned to preserve both competitive pricing and reliable patient access.

Segmentation insights reveal how radiometal, peptide, indication, and access choices shape SSTR radioconjugate adoption

Understanding the targeted SSTR radionuclide drug conjugate landscape requires a nuanced view of how different technological, clinical, and commercial segments interact. Radiometal selection is foundational, with Lutetium 177 currently at the center of established clinical practice due to its favorable half-life, beta emission profile, and compatibility with existing hospital infrastructure. Actinium 225, while less mature, is attracting strong interest for patients with aggressive or resistant disease, leveraging its potent alpha emissions to tackle micro-metastatic and poorly vascularized lesions. Yttrium 90 remains important in settings that benefit from deeper tissue penetration, but its use demands careful balancing of efficacy against potential off-target toxicity, making patient selection and dosimetry critical.

Parallel to radiometal choice, peptide analog differentiation is becoming a key lever for clinical optimization and market positioning. Dotatate has gained prominence through strong clinical evidence and broad familiarity among nuclear medicine and oncology teams, particularly for midgut neuroendocrine tumors. Dotatoc is often explored where pharmacokinetic or binding characteristics could confer advantages in specific tumor subtypes or anatomical sites, while Dotanoc's broader receptor subtype affinity profile is being studied for applications that may require more extensive tumor targeting. Together, these analogs support a more personalized approach, where peptide selection is increasingly aligned with tumor biology, imaging findings, and safety considerations.

Treatment indication segmentation underscores how clinical practice is evolving. Neuroendocrine tumors remain the primary focus, benefiting from high SSTR expression, robust imaging guidance, and growing familiarity with peptide receptor radionuclide therapy among specialists. Within this group, heterogeneity across gastrointestinal, pancreatic, and bronchial subtypes is prompting more tailored use of specific radiometal-peptide combinations. Thyroid cancer is emerging as a significant extension area, especially for patients who are refractory to radioiodine or targeted systemic therapies. Here, SSTR-directed conjugates offer a complementary modality, but their adoption depends heavily on interdisciplinary collaboration between endocrinology, nuclear medicine, and surgical teams.

Clinical phase distribution highlights a dynamic pipeline that spans commercial products with established practices and a substantial cohort of investigational agents. Commercially available therapies continue to define current standards of care and inform health technology assessments, while Phase I programs explore new radiometal-peptide pairings, novel chelators, and first-in-human safety parameters. Phase II studies are concentrating on dose optimization, comparative performance in defined subpopulations, and potential combination strategies, whereas Phase III trials aim to solidify earlier-line use, expanded indications, and head-to-head positioning against existing standards. Preclinical work remains robust, particularly around alpha-emitters, next-generation peptides, and cross-indication applications.

End user dynamics shape how these therapies reach patients. Hospitals with established nuclear medicine departments serve as the primary hubs for administration, leveraging multidisciplinary teams and in-house radiopharmacy capabilities. Research institutes play a pivotal role in early-phase trials, imaging innovation, and translational work that refines indication selection and dosing. Specialty clinics, including dedicated neuroendocrine and endocrine oncology centers, are emerging as important access points, especially in regions where hospital capacity is constrained or where concentrated expertise enables high-volume, protocol-driven therapy delivery.

The distribution channel structure further influences market behavior. Direct procurement arrangements between manufacturers and large hospital systems or specialized centers allow for tighter coordination on just-in-time delivery, quality control, and pricing. Distributor sales facilitate broader geographic reach, particularly for centers without the scale or infrastructure to manage complex supply chains independently. Tender-based procurement, common in public and large private healthcare networks, introduces competitive pricing dynamics and encourages suppliers to differentiate through reliability, support services, and clinical education. In combination, these segmentation dimensions reveal a market where technology choices, clinical development strategies, and access models must be tightly aligned to deliver consistent value to patients and providers.

Regional dynamics across Americas, EMEA, and Asia-Pacific dictate access, capacity, and growth pathways for SSTR radiotherapeutics

Regional dynamics play a decisive role in shaping the evolution and adoption of targeted SSTR radionuclide drug conjugates, with distinct patterns emerging across the Americas, Europe, Middle East and Africa, and Asia-Pacific. In the Americas, the United States anchors clinical use and innovation, driven by strong academic nuclear medicine centers, a favorable regulatory environment for radiopharmaceuticals, and the presence of integrated manufacturers capable of supporting complex supply chains. Access to Lutetium 177-based therapies is relatively advanced in leading cancer centers, and there is significant investment in expanding Actinium 225 and other alpha-based programs. Canada and select Latin American countries are gradually increasing adoption, although disparities in infrastructure, reimbursement, and specialist availability create uneven access within the region.

Across Europe, Middle East and Africa, the environment is heterogeneous but generally supportive of advanced nuclear medicine. Many European countries have long-standing expertise in both diagnostic and therapeutic nuclear medicine, supported by coordinated networks of academic centers and public hospitals. European regulators have been proactive in setting standards for radiopharmaceutical production and dosimetry, which has helped establish high-quality clinical practice for SSTR-targeted therapies. However, variation in reimbursement frameworks and national procurement policies creates differences in patient access, with some countries benefiting from early adoption while others move more slowly due to budget constraints or limited infrastructure.

Within the Middle East, a small but growing number of centers are building capacity for peptide receptor radionuclide therapy, often in partnership with European or North American institutions. Investments in oncology centers of excellence and nuclear medicine capabilities are beginning to translate into more consistent availability of Lutetium 177-based treatments. In Africa, access remains more constrained, with only a handful of countries possessing the necessary infrastructure and regulatory frameworks to support routine clinical use. International collaborations, training initiatives, and technology transfer programs will be essential for expanding availability across this diverse region.

Asia-Pacific presents a mix of rapid expansion and persistent gaps. Countries such as Japan, South Korea, Australia, and Singapore are demonstrating strong growth in nuclear medicine capacity, backed by robust healthcare systems, active clinical research, and supportive regulatory environments. These markets are often at the forefront of adopting new radiometal and peptide analog combinations, as well as advancing SSTR imaging sciences. In contrast, several emerging economies in the region face challenges in establishing radiopharmaceutical production, regulatory oversight, and specialized workforce training, which slows the uptake of targeted SSTR radionuclide therapies.

Despite these differences, there are cross-cutting regional trends that shape the global outlook. Demand for advanced neuroendocrine and thyroid cancer management is rising in all three broad regions, fueled by improved diagnostic capabilities and growing awareness of the benefits of personalized radioligand therapy. At the same time, international guidelines and consensus statements are encouraging more standardized use of imaging, dosimetry, and follow-up across borders, which may gradually reduce variability in clinical practice.

Looking forward, regional collaboration will become increasingly important. Shared manufacturing arrangements, cross-border clinical trials, and harmonized regulatory pathways could alleviate some of the supply and access constraints seen in parts of Europe, Middle East and Africa and Asia-Pacific. For companies operating in this field, understanding these regional nuances is essential to designing realistic expansion plans, aligning distribution strategies with local infrastructure, and tailoring medical education and support programs to the maturity level of each market.

Company strategies, partnerships, and manufacturing models shape competitive positioning in SSTR-targeted radioconjugates

Company strategies are a critical determinant of how the targeted SSTR radionuclide drug conjugate field is evolving, with both large pharmaceutical organizations and specialized radiopharmaceutical firms shaping direction. Established industry leaders are leveraging their resources, regulatory experience, and existing oncology portfolios to scale commercial Lutetium 177-based offerings, extend indications, and invest in lifecycle management programs. These efforts often include post-marketing studies, real-world evidence generation, and collaborations with leading cancer centers to refine patient selection criteria and long-term safety monitoring.

At the same time, smaller biotechnology and radiopharmaceutical companies are acting as innovation engines, particularly in areas such as Actinium 225 alpha-emitting payloads, novel peptide analogs, and improved chelation chemistry. Many of these companies focus on early-stage development and rely on strategic partnerships, licensing deals, or acquisitions to bring products through late-stage trials and commercialization. This dynamic has created an active deal-making environment, where larger players seek access to differentiated assets and platform technologies that can complement or extend their existing SSTR-targeted portfolios.

A notable trend is the integration of diagnostic and therapeutic capabilities into unified theranostic platforms. Companies with strengths in SSTR-PET imaging agents, for example, are well positioned to offer end-to-end solutions that include both imaging and therapeutic radioconjugates. This integrated approach not only supports efficient patient selection and treatment response monitoring but also creates stickier relationships with hospitals and specialty clinics that value consistency of supply, training, and service.

Manufacturing strategy is another defining dimension of company differentiation. Some firms are investing heavily in vertically integrated production networks, combining radionuclide generation, peptide synthesis, radiolabeling, and final product distribution under a single operational umbrella. This model can enhance control over quality, cost, and supply reliability but requires significant capital investment and technical expertise. Other companies adopt a more partnership-oriented approach, working with contract manufacturing organizations and regional radiopharmacies to achieve scalability and geographic reach without owning all assets directly.

Companies are also increasingly attentive to health economics and outcomes research as a strategic lever. By generating robust evidence on quality of life improvements, hospitalization reductions, and long-term outcomes, they aim to strengthen value propositions in negotiations with payers, especially in tender-driven or budget-constrained settings. Some organizations are experimenting with innovative pricing and access models, such as outcomes-linked agreements, to facilitate reimbursement for high-complexity therapies.

Finally, talent and capability development are emerging as competitive differentiators. Organizations that successfully combine deep expertise in nuclear medicine, peptide chemistry, regulatory science, and oncology market access are better positioned to navigate the unique challenges of this field. Targeted recruitment, strategic academic partnerships, and internal training programs are therefore central components of leading company strategies as they prepare for continued expansion of SSTR-targeted radionuclide drug conjugate therapies.

Actionable strategies enable industry leaders to optimize pipelines, resilience, and access in SSTR radionuclide therapeutics

Industry leaders operating in the targeted SSTR radionuclide drug conjugate space can take several concrete steps to strengthen their strategic position and enhance patient impact. A first priority is to deepen integration between radiochemistry innovation and clinical development planning. Rather than treating radiometal and peptide analog selection as isolated technical decisions, companies should align these choices with clearly defined clinical hypotheses and target patient segments, particularly within neuroendocrine tumors and thyroid cancer. Early engagement with key opinion leaders can help refine these hypotheses, ensuring that pipeline assets address unmet needs and fit within real-world treatment pathways.

Another actionable recommendation is to invest in robust theranostic infrastructure and partnerships. Companies should support the combined use of SSTR-PET imaging and therapeutic conjugates by providing clear protocols, training materials, and data collection frameworks to hospitals and specialty clinics. This will not only improve patient selection and outcome monitoring but also generate the high-quality evidence required by regulators and payers. Collaborations with research institutes can further accelerate the development of standardized dosimetry protocols, which are essential for optimizing efficacy and minimizing toxicity.

Given the evolving trade and tariff environment, leaders must also prioritize supply chain resilience. This involves diversifying radiometal sources across multiple regions, establishing contingency manufacturing options, and integrating real-time logistics monitoring systems. Proactive scenario planning around U.S. tariffs and other geopolitical risks can inform contract structures, pricing strategies, and investment decisions. By building redundancy and transparency into their supply networks, companies can reduce the risk of treatment interruptions and maintain the confidence of providers and patients.

On the commercial side, industry leaders should tailor engagement strategies to the specific needs of hospitals, research institutes, and specialty clinics. Hospitals may require comprehensive support packages that include training, workflow optimization, and radiation safety guidance. Research institutes typically value access to novel agents, data-sharing arrangements, and co-authorship opportunities in scientific publications. Specialty clinics may prioritize reliable delivery, streamlined ordering systems, and patient education tools. Aligning sales, medical affairs, and support services with these differentiated needs will foster stronger, more sustainable relationships across the care continuum.

Payer and policymaker engagement is equally important. Companies should develop clear, data-driven narratives that articulate the clinical and economic contributions of SSTR-targeted radionuclide therapies. This includes highlighting reductions in hospitalization, improvements in functional status, and potential productivity gains for patients. Early dialogue with health technology assessment bodies and insurers can identify evidence gaps, guide trial design, and position therapies for favorable reimbursement decisions, particularly in tender-oriented markets.

Finally, leaders should cultivate organizational capabilities that reflect the multidisciplinary nature of this field. Investing in cross-functional teams that span nuclear medicine, medical oncology, regulatory affairs, market access, and health economics will enable more agile decision-making and effective execution. Structured internal learning programs, rotations between functions, and strong collaboration with academic partners can help build the expertise needed to navigate the complexities of targeted SSTR radionuclide drug conjugates in an increasingly competitive environment.

Robust multi-source research methodology underpins strategic insights into SSTR-targeted radionuclide drug conjugates

The analysis underlying this executive summary is built on a structured, multi-layered research methodology designed to capture the scientific, clinical, regulatory, and commercial nuances of targeted SSTR radionuclide drug conjugates. The research approach integrates extensive secondary information with validation and contextualization from primary expert insights, while maintaining strict quality control standards and triangulation techniques.

The first step involves comprehensive secondary research to map the current landscape. This includes an in-depth review of peer-reviewed scientific and medical literature on somatostatin receptor biology, peptide analog development, radiometal characteristics, and clinical outcomes in neuroendocrine tumors and thyroid cancer. Regulatory databases and public health agency documents provide information on approved therapies, ongoing clinical trials, pharmacovigilance updates, and evolving guidelines for radiopharmaceutical production and use. Professional society guidelines and consensus statements inform best practices in imaging, dosimetry, and patient selection.

In parallel, clinical trial registries and company disclosures are examined to characterize the pipeline across preclinical, Phase I, Phase II, Phase III, and commercial stages. This allows for a structured view of how radiometal types such as Lutetium 177, Yttrium 90, and Actinium 225 are being deployed, which peptide analogs are prioritized, and how indications are expanding beyond traditional neuroendocrine settings. Publicly available information on manufacturing facilities, supply agreements, and strategic partnerships further illuminates how companies are configuring their operational footprints and go-to-market approaches.

Secondary research is complemented by targeted primary insights from clinicians, researchers, and industry participants with direct experience in SSTR-targeted radionuclide therapy. These discussions help validate assumptions, clarify regional practice patterns, and highlight emerging issues such as tariff impacts, reimbursement challenges, and infrastructure bottlenecks. Input from nuclear medicine specialists, medical oncologists, and health economists is particularly valuable for understanding how clinical outcomes translate into real-world adoption and payer decision-making.

To ensure robustness, the research process employs triangulation, comparing data points and perspectives from multiple independent sources before drawing conclusions. For example, clinical practice trends identified in expert interviews are cross-checked against published registries and real-world evidence studies, while company strategy assessments are validated through multiple public disclosures and independent commentary. Any discrepancies are examined in detail, and interpretations are adjusted to reflect the weight and reliability of available evidence.

Analytical frameworks are applied to organize findings into coherent segments, covering radiometal type, peptide analog, treatment indication, clinical phase, end user profile, and distribution channel. Regional analysis follows a similar structure, examining differences and commonalities across the Americas, Europe, Middle East and Africa, and Asia-Pacific. Throughout the process, the research deliberately avoids speculative quantification or unsupported projections, focusing instead on qualitative trends, structural drivers, and emerging patterns supported by verifiable data.

Quality assurance mechanisms, including internal peer review and consistency checks across sections, help maintain accuracy and clarity. All sources are evaluated for credibility, timeliness, and relevance, with preference given to recent, peer-reviewed, or officially sanctioned information. This methodology ensures that the insights presented here offer a reliable, nuanced foundation for strategic decision-making in the targeted SSTR radionuclide drug conjugate arena.

Convergence of innovation, evidence, and access positions SSTR radionuclide conjugates at an oncology inflection point

Targeted SSTR radionuclide drug conjugates are transitioning from specialized interventions to integral components of modern oncology practice, particularly for neuroendocrine tumors and select thyroid cancers. By harnessing the specificity of somatostatin receptor-binding peptides and the cytotoxic power of therapeutic radionuclides, these agents deliver a compelling combination of efficacy, organ preservation, and quality-of-life benefits for appropriately selected patients. Advances in radiometal chemistry, peptide engineering, and dosimetry have strengthened the clinical foundation for wider adoption, while the maturing pipeline signals continued innovation across both beta- and alpha-emitting platforms.

This evolution, however, brings challenges that require coordinated responses from industry, healthcare providers, regulators, and payers. Supply chain complexity, highlighted by the imp

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Targeted SSTR Radionuclide Drug Conjugates Market, by Radiometal Type

  • 8.1. Actinium 225
  • 8.2. Lutetium 177
  • 8.3. Yttrium 90

9. Targeted SSTR Radionuclide Drug Conjugates Market, by Peptide Analog

  • 9.1. Dotanoc
  • 9.2. Dotatate
  • 9.3. Dotatoc

10. Targeted SSTR Radionuclide Drug Conjugates Market, by Treatment Indication

  • 10.1. Neuroendocrine Tumors
  • 10.2. Thyroid Cancer

11. Targeted SSTR Radionuclide Drug Conjugates Market, by Clinical Phase

  • 11.1. Commercial
  • 11.2. Phase I
  • 11.3. Phase II
  • 11.4. Phase III
  • 11.5. Preclinical

12. Targeted SSTR Radionuclide Drug Conjugates Market, by End User

  • 12.1. Hospital
  • 12.2. Research Institutes
  • 12.3. Specialty Clinics

13. Targeted SSTR Radionuclide Drug Conjugates Market, by Distribution Channel

  • 13.1. Direct Procurement
  • 13.2. Distributor Sales
  • 13.3. Tender

14. Targeted SSTR Radionuclide Drug Conjugates Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Targeted SSTR Radionuclide Drug Conjugates Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Targeted SSTR Radionuclide Drug Conjugates Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Targeted SSTR Radionuclide Drug Conjugates Market

18. China Targeted SSTR Radionuclide Drug Conjugates Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Actinium Pharmaceuticals, Inc.
  • 19.6. ACUITY Pharmaceuticals, Inc.
  • 19.7. Bayer AG
  • 19.8. Cardinal Health, Inc.
  • 19.9. Curium Pharma GmbH
  • 19.10. Eckert & Ziegler Radiopharma GmbH
  • 19.11. GE Healthcare Limited
  • 19.12. Ipsen SA
  • 19.13. Isoray Medical, Inc.
  • 19.14. ITM Isotope Technologies Munich SE
  • 19.15. Jubilant Life Sciences Limited
  • 19.16. Lantheus Holdings, Inc.
  • 19.17. Novartis AG
  • 19.18. Point Biopharma Inc.
  • 19.19. PSMA Therapeutics LLC
  • 19.20. RadioMedix, Inc.
  • 19.21. RayzeBio, Inc.
  • 19.22. Sorrento Therapeutics, Inc.
  • 19.23. Telix Pharmaceuticals Limited
  • 19.24. Theragnostics, Inc.
  • 19.25. Viamet Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ACTINIUM 225, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ACTINIUM 225, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ACTINIUM 225, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY LUTETIUM 177, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY LUTETIUM 177, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY LUTETIUM 177, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY YTTRIUM 90, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY YTTRIUM 90, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY YTTRIUM 90, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DOTANOC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DOTANOC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DOTANOC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DOTATATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DOTATATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DOTATATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DOTATOC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DOTATOC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DOTATOC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THYROID CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THYROID CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THYROID CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DIRECT PROCUREMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DIRECT PROCUREMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DIRECT PROCUREMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTOR SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTOR SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTOR SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TENDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TENDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. GCC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2032 (USD MILLION)
  • TABLE 133. GCC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. GCC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 135. GCC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. GCC TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. G7 TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2032 (USD MILLION)
  • TABLE 154. G7 TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. G7 TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 156. G7 TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. G7 TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. NATO TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2032 (USD MILLION)
  • TABLE 161. NATO TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. NATO TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 163. NATO TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. NATO TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIOMETAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PEPTIDE ANALOG, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TREATMENT INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINICAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA TARGETED SSTR RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)